- Home
- JAZZ vs DOCN Comparison
JAZZ vs DOCN Comparison
Compare JAZZ & DOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | DOCN |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 13.2B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | DOCN |
|---|---|---|
| Price | $239.79 | $129.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $217.57 | $85.46 |
| AVG Volume (30 Days) | 877.4K | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 183.15 |
| EPS | ★ 7.17 | 0.45 |
| Revenue | ★ $1,618,693,000.00 | $901,427,000.00 |
| Revenue This Year | $6.22 | $23.80 |
| Revenue Next Year | $7.68 | $30.11 |
| P/E Ratio | ★ $34.01 | $295.51 |
| Revenue Growth | N/A | ★ 15.48 |
| 52 Week Low | $125.79 | $33.69 |
| 52 Week High | $266.38 | $187.50 |
Technical Indicators
Market Signals| Indicator | JAZZ | DOCN |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 53.68 |
| Support Level | $236.70 | $126.05 |
| Resistance Level | $242.66 | $140.15 |
| Average True Range (ATR) | 5.77 | 8.35 |
| MACD | -0.36 | 1.74 |
| Stochastic Oscillator | 32.04 | 72.74 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.